Synklino
Strives to provide rapid relief and improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
€302k | Grant | ||
| Total Funding | 000k | ||
| DKK | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Synklino is a biotechnology company focused on developing innovative treatments to eliminate cytomegalovirus (CMV) infections in transplant recipients. Operating in the healthcare and biotech market, Synklino serves patients who have undergone organ and stem cell transplants, providing them with a crucial safeguard against CMV, which can be devastating post-transplant. The company's business model revolves around the research, development, and commercialization of its proprietary treatments, generating revenue through the sale of these specialized medical solutions. By ensuring the elimination of CMV infections, Synklino helps patients recover faster and maintain their quality of life post-transplant.
Keywords: biotechnology, CMV, transplant, healthcare, innovation, treatment, quality of life, infection prevention, medical solutions, commercialization.